ID: ALA3970950

Max Phase: Preclinical

Molecular Formula: C11H11N3O2

Molecular Weight: 217.23

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NO)c1ccc(Cn2cccn2)cc1

Standard InChI:  InChI=1S/C11H11N3O2/c15-11(13-16)10-4-2-9(3-5-10)8-14-7-1-6-12-14/h1-7,16H,8H2,(H,13,15)

Standard InChI Key:  DUGDSZFLAKVUEC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 217.23

Molecular Weight (Monoisotopic): 217.0851

AlogP: 1.05

#Rotatable Bonds: 3

Polar Surface Area: 67.15

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.20

CX Basic pKa: 2.07

CX LogP: 0.97

CX LogD: 0.97

Aromatic Rings: 2

Heavy Atoms: 16

QED Weighted: 0.60

Np Likeness Score: -2.19

References

1.  (2016)  HDAC inhibitors and therapeutic methods using the same, 

2. Vergani B, Sandrone G, Marchini M, Ripamonti C, Cellupica E, Galbiati E, Caprini G, Pavich G, Porro G, Rocchio I, Lattanzio M, Pezzuto M, Skorupska M, Cordella P, Pagani P, Pozzi P, Pomarico R, Modena D, Leoni F, Perego R, Fossati G, Steinkühler C, Stevenazzi A..  (2019)  Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.,  62  (23): [PMID:31710483] [10.1021/acs.jmedchem.9b01194]

3. Shen S, Svoboda M, Zhang G, Cavasin MA, Motlova L, McKinsey TA, Eubanks JH, Bařinka C, Kozikowski AP..  (2020)  Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor.,  11  (5): [PMID:32435374] [10.1021/acsmedchemlett.9b00560]

Source

Source(2):

• Scientific Literature
• BindingDB Database